COVID-19: WHO resumes study on Hydroxychloroquine

Few days after the World Health Organisation, WHO, suspended trial on hydroxychloroquine over safety concerns, the world health body says it will be resuming trial on the controversial drug for the treatment of COVID-19 patients.

It could be recalled that WHO had last week temporarily suspended trail on the drug under a larger study called ‘Solidarity Trial’ that is investigating a number of different potential Coronavirus therapies, due to concerns about the hydroxychloroquine’s adverse effects on the heart.

The trial’s Data Safety and Monitoring Committee halted the study as a precaution in response to safety concerns raised by an observational study published in the Lancet.

“This decision was taken as a precaution while the safety data were reviewed. The Data Safety and Monitoring Committee of the Solidarity Trial has been reviewing the data.

“On the basis of available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol.

“The Executive Group received this recommendation and endorsed the continuation of all arms of the Solidarity Trial, including hydroxychloroquine.

“WHO is committed to accelerating the development of effective therapeutics, vaccines, and diagnostics as part of our commitment to serving the world with science, solutions, and solidarity,’’ he said.

Meanwhile, the Director-General of the National Agency for Food and Drug Administration and Control, NAFDAC, Prof. Christianah Adeyeye, said Nigeria would continue with the trial of the drug.

7 Comments

Leave a Reply